A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
Trial
Phase 1
Completed
Nov. 28, 2019
A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects
Trial
Phase 1
Completed
Nov. 28, 2019
Effects of Combined rTMS and Treadmill Training in People With Parkinson's Disease
Trial
N/A
Completed
Nov. 21, 2019
P-glycoprotein Function in Brain Diseases
Trial
N/A
Completed
Nov. 21, 2019
Genetics of Motor Learning
Trial
N/A
Terminated
Nov. 21, 2019
Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation
Trial
N/A
Completed
Nov. 20, 2019
Telephone-linked Home-based Exercise Training in PD
Trial
N/A
Completed
Nov. 20, 2019
Transcutaneous Spinal Cord Stimulation for Parkinson Disease
Trial
N/A
Unknown
Nov. 19, 2019
Effectiveness of a Program With Aquatic Therapy in Patients With Parkinson's Disease Clinical Trial
Trial
N/A
Unknown
Nov. 19, 2019
Emotional Prosody Treatment in Parkinson's
Trial
N/A
Completed
Nov. 17, 2019
Dual Task Training in Parkinson's Disease
Trial
N/A
Unknown
Nov. 17, 2019
Combined Deep Brain Stimulation for Parkinson's Disease
Trial
Phase 1
Withdrawn
Nov. 14, 2019
Effects of Cholinergic Augmentation on Measures of Balance and Gait
Trial
Phase 2
Completed
Nov. 13, 2019
Priming Through Timing. Using Opposing Strategies to Enhance Motor Learning for Individuals With Parkinson's Disease
Trial
N/A
Completed
Nov. 12, 2019
Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease
Trial
Phase 3
Terminated
Nov. 12, 2019
A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
Trial
Phase 2
Completed
Nov. 7, 2019
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
Trial
Phase 3
Completed
Nov. 7, 2019
Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
Trial
Phase 3
Completed
Nov. 6, 2019
Pilot Trial of Transnasal Nicotine in Parkinson Disease
Trial
Phase 2
Completed
Nov. 5, 2019
A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease
Trial
Phase 2
Completed
Nov. 5, 2019